Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 222

Similar articles for PubMed (Select 21752491)

1.

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.

Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.

J Am Acad Dermatol. 2012 Feb;66(2):241-51. doi: 10.1016/j.jaad.2010.12.005. Epub 2011 Jul 14.

PMID:
21752491
2.

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.

Papp K, Menter A, Poulin Y, Gu Y, Sasso EH.

J Eur Acad Dermatol Venereol. 2013 May;27(5):634-42. doi: 10.1111/j.1468-3083.2012.04515.x. Epub 2012 Mar 16.

PMID:
22429586
3.

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.

Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C.

J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1007-13. doi: 10.1111/j.1468-3083.2011.04225.x. Epub 2011 Oct 25.

PMID:
22023702
4.

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.

Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.

J Am Acad Dermatol. 2010 Sep;63(3):448-56. doi: 10.1016/j.jaad.2009.09.040. Epub 2010 Jun 3.

PMID:
20605254
5.

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.

Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM.

Br J Dermatol. 2012 Sep;167(3):658-67. doi: 10.1111/j.1365-2133.2012.11041.x. Epub 2012 Aug 20.

PMID:
22564148
6.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K.

J Am Acad Dermatol. 2008 Jan;58(1):106-15. Epub 2007 Oct 23.

PMID:
17936411
7.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

8.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
9.

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.

Arch Dermatol. 2005 Jan;141(1):31-8.

PMID:
15655139
10.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.

Arthritis Rheum. 2007 Feb;56(2):476-88.

PMID:
17265483
11.

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.

Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20.

PMID:
21173304
12.

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.

Asahina A, Nakagawa H, Etoh T, Ohtsuki M; Adalimumab M04-688 Study Group.

J Dermatol. 2010 Apr;37(4):299-310. doi: 10.1111/j.1346-8138.2009.00748.x.

PMID:
20507398
13.

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.

Br J Dermatol. 2012 Apr;166(4):861-72. doi: 10.1111/j.1365-2133.2012.10901.x.

PMID:
22356258
14.

An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.

Taniguchi T, Noda S, Takahashi N, Yoshimura H, Mizuno K, Adachi M.

J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1444-7. doi: 10.1111/j.1468-3083.2012.04610.x. Epub 2012 Jun 15.

PMID:
22702802
15.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
16.

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M.

J Am Acad Dermatol. 2014 Dec;71(6):1176-82. doi: 10.1016/j.jaad.2014.07.048. Epub 2014 Sep 19.

PMID:
25242558
17.

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.

Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators.

J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. doi: 10.1111/jdv.12046. Epub 2012 Dec 20.

PMID:
23279003
18.

Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.

Van L├╝mig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.

Br J Dermatol. 2010 Oct;163(4):838-46. doi: 10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2.

PMID:
20649798
19.

Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.

Noda S, Mizuno K, Adachi M.

J Dermatol. 2012 Mar;39(3):265-8. doi: 10.1111/j.1346-8138.2011.01312.x. Epub 2011 Nov 29.

PMID:
22126280
20.

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.

Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM.

J Am Acad Dermatol. 2006 Oct;55(4):598-606. Epub 2006 Aug 10.

PMID:
17010738
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk